|
|
||||||||
J Thorac Cardiovasc Surg 2003;125:1050-1057
© 2003 The American Association for Thoracic Surgery
Surgery for Congenital Heart Disease |
From the Laboratory of Experimental Surgery, Marie-Lannelongue Hospital, Le Plessis-Robinson, France.
Received for publication Jan 8, 2002. Revisions requested April 1, 2002; revisions received July 24, 2002. Accepted for publication Aug 2, 2002. Address for reprints: Alain Serraf, MD, Marie-Lannelongue Hospital, 133 ave de la Résistance, 92350, Le Plessis-Robinson, France (E-mail: aserraf{at}ccml.com).
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
Recently a strong body of publications have shown a tight relation between nitric oxide production and vascular endothelial growth factor (VEGF). VEGF is a soluble 46-kd angiogenic glycoprotein that exerts its biologic function through high-affinity tyrosine kinase receptors.
4 VEGF has been shown to have several biologic functions. In addition to its involvement in angiogenesis, it induces an endothelium-dependent vasodilatation that is inhibited by nitric oxide synthase (NOS) inhibitors.
5 Brock and colleagues
6 demonstrated that VEGF increased cytosolic calcium, which promotes calmodulin binding to the endothelial isoform of NOS and stimulates nitric oxide production.
7 More recently, this effect of VEGF on nitric oxide production has been associated with upward regulation of endothelial cell NOS activity.
8 In addition, VEGF has been recognized to be encoded by the very same gene that encodes for vascular permeability factor, a protein that promotes extravasation of proteins from tumor-associated blood vessels.
9 In addition, VEGF has been demonstrated to prevent endothelial cell apoptosis through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway
10 and inhibits leukocyte-endothelium interactions.
11
Hypoxia and ischemia are major stimulators of VEGF expression.
12 Hypoxia-induced transcription of VEGF messenger RNA is apparently mediated at least in part by the binding of hypoxia-inducible factor 1 to a hypoxia-inducible factor 1 binding site located in the VEGF promoter.
13 Interleukin 1ß and interleukin 6 are also strong stimulators of VEGF production.
14
We therefore hypothesize that during CPB, strong stimulation for VEGF lung production or receptors expression might be present through hypoxia-ischemia mechanisms as well as through the production of various cytokines. Therefore an increase in pulmonary vascular lung nitric oxide production should be observed, which is in contrast with previous observations, namely decreases in nitric oxide production
15 and endothelial cell apoptosis
16,17 and increased leukocyte-endothelium interactions.
3 This study was an attempt to demonstrate that during CPB there is a stimulus for lung VEGF accumulation but that signal transduction to produce nitric oxide fails. In addition, if VEGF is produced in excess, capillary permeability should be increased.
| Material and methods |
|---|
|
|
|---|
Twenty-five neonatal piglets (mean age 7 days, mean weight 3.2 kg) were purchased from a local farmer. All animals received humane care in compliance with the "Principles of Laboratory Animal Care" formulated by the National Society for Medical Research and the Guide for the Care and Use of Laboratory Animals prepared by the Institute of Laboratory Animal Resources, National Research Council, and published by the National Academy Press, revised 1996. They were kept without food for 12 hours before the operation, sedated with intramuscularly injected ketamine (10-15 mg/kg), and anesthetized with thiopental (3-5 mg/kg intravenously). Analgesia was maintained throughout the experimentation with fentanyl (3-5 µg/[kg · min]). Subsequently, the animals were intubated and general anesthesia was maintained with nitrous oxide (60%) and oxygen (40%) under intermittent positive-pressure ventilation (MMS 107 ventilator; S.N.E.H., Gonesse, France) at 40 breaths/min with a tidal volume of 15 mL/kg. With the animal in a supine position, the right femoral artery was isolated. After femoral arterial cannulation, ventilatory rate and tidal volume were adjusted to establish a normal pH and PCO2, as determined by arterial blood gas measurement (ABL2; Radiometer Medical A/S, Brønshøj, Denmark). After midline sternotomy and pericardiotomy, the ductus was ligated and the great vessels were controlled. A pulmonary artery catheter (Intracath, Deseret Medical, Inc, Sandy, Utah) was introduced into the main pulmonary artery through the right ventricular infundibulum, and cardiac output was recorded with a Doppler probe placed around the pulmonary artery trunk (model T106 M; Transonic Systems, Inc, Ithaca, NY). The central venous and left atrial pressures were monitored after placement of indwelling catheters in the right and left atria. Pressure recording was performed with the P23 ID Statham pressure transducer (Statham, Paris, France). After heparin administration (3 mg/kg), CPB was instituted between the right atrium with the arterial return directed into the ascending aorta. The bypass circuit consisted in a cardiotomy reservoir and a membrane oxygenator (Safe Micro; Polystan A/S, Vjrlose, Denmark), a heat exchanger, and a roller pump. No arterial filter was used. The circuit was primed (400 mL) with whole blood obtained from a donor pig the day before surgery. Within the first 5 minutes of CPB, a vent was introduced through the left ventricular apex. Mean systemic arterial pressures were maintained to prebypass values with a mean flow of 500 mL/min. After a steady state was obtained under CPB, ventilation was stopped and cooling to 33°C was started. The pulmonary artery trunk was crossclamped to avoid any antegrade flow to the lungs, and CPB was maintained for 90 minutes without aortic crossclamping. After this period mechanical ventilation was reinstituted and the piglets were weaned from CPB. They were allowed to survive 2 hours and then killed. The pulmonary arterial vessels were dissected beyond the second-generation branch and mounted in an organ chamber for vascular reactivity evaluation.
Physiologic measurements
Hemodynamic measurements were made before institution of CPB and 120 minutes after cessation of CPB. Cardiac output was determined as pulmonary blood flow (Qpa) in liters per minute. PVR was calculated as follows:
PVR = (PAP - LAP)/Qpa x 79.9
where PAP is the mean pulmonary arterial pressure and LAP is the mean left atrial pressure.
Biopsy specimens were obtained from the lungs (n = 16) and from skeletal muscle (n = 5) before and 120 minutes after CPB for VEGF assessment. They were frozen at -80°C until processing.
Evaluation of lung nitric oxide production
Exhaled nitric oxide was measured as follow. The expiratory circuit was disconnected from the ventilator and connected to a polypropylene bag (150 mL). Nitric oxide was immediately measured within the bag with a rapid-response chemiluminescent analyzer (NOX 4000; SERES, Aix en Provence, France). The analyzer was calibrated before use with serial dilutions of a standard nitric oxide gas. The lower limit of the sensitivity was 2 ppb. Measurements of inspired gas in the room were taken as a prelude to the investigation and suggested a level of 2 ppb nitric oxide. At each measurement the mean of three samples was recorded. Although this method does not eliminate upper airway nitric oxide metabolism, prebypass and postbypass values were assumed to include the same bias.
Lung and muscular VEGF assessment
VEGF assessment was performed according to the method described by Turnage and coworkers.
18 Tissues were pulverized and homogenized with a Polytron homogenizer (Brinkmann Instruments, Inc, Westbury, BY) in a buffer solution (tris[hydroxymethyl]aminomethane hydrochloride at 0.05 mol/L and ethylenediaminetetraacetic acid at 0.1 mmol/L, pH 7,40) containing protease inhibitors (leupeptin at 10 µmol/L, pepstatin at 1 µmol/L, phenylmethylsulfonyl fluoride at 1 mmol/L) and 3-[(3-cholamidopropyl)dimethylammonio]-1-propane sulfonate at 20 mmol/L. The homogenate was sonicated on ice for 15 seconds, frozen (at -70°C) and thawed two times, and then centrifuged at 40000g for 20 minutes. VEGF concentration in the supernatant was then assessed with specific antibody for human VEGF165 (Quantikine; R&D Systems, Minneapolis, Minn). Results are expressed in picograms per 100 mg tissue.
Isolated pulmonary arterial ring studies
At the end of each experiment, left and right intrapulmonary arterial segments were dissected out and placed in warm Krebs-Henseleit buffer composed of 118.3-mmol/L sodium chloride, 4.7-mmol/L potassium chloride, 2.5-mmol/L calcium chloride, 1.2-mmol/L potassium phosphate, 1.2-mmol/L magnesium sulfate, 25-mmol/L sodium hydrogen carbonate, 0.03-mmol/L ethylenediaminetetraacetic acid, and 11.1-mmol/L glucose. Isolated pulmonary arteries were cleaned and cut into rings 3 to 4 mm in length (1-2 mm outer diameter). From 12 to 16 rings were obtained from each animal. The rings were then mounted on stainless steel hooks, suspended in 10-mL tissue baths, and connected to force displacement transducers (LB-5; Showa-Sokki Corp, Tokyo, Japan) to record changes in force by the use of chart recorder (LR 4210; Yokogawa Corporation of America, Newman, Ga). The baths were filled with 10 mL Krebs-Henseleit buffer and aerated at 37°C with a gas mixture of 95% oxygen and 5% carbon dioxide. Pulmonary arterial rings were initially stretched to produce a preload of 1g of force and equilibrated for 60 to 90 minutes. A preload of 1g was proved to be the optimal resting tension by length-tension analyses performed in pilot studies. This value is close to the optimal resting tension (1.060g ± 0.040g) found by Liu and coworkers
19 in piglet neonatal pulmonary arterial rings. During this period, the Krebs-Henseleit buffer in the tissue baths was replaced every 10 minutes. After incubation with indomethacin (10-5 mol/L) for 60 minutes, a concentration-response curve to phenylephrine was obtained. The rings were then washed, and the developed force was allowed to return to baseline. The rings were then precontracted with phenylephrine to generate 1g of developed force. Once a stable contraction was obtained, different pharmacologic protocols were performed.
In addition to the change in force, responses were assessed by determining the concentration that produced 50% of the maximal response (EC50), extrapolated from a plot of log concentration versus percentage of maximal response. The contractile response to phenylephrine were expressed in absolute values (g), and the maximum relaxations to acetylcholine and calcium ionophore were expressed as percentages of the phenylephrine-induced precontraction, with 0% indicating no relaxation and 100% indicating a relaxation equals to that of the precontraction. Post-CPB pulmonary arterial rings were compared with control pulmonary arterial rings obtained from matched piglets that did not undergo CPB.
Isolated perfused lung
The left lung was harvested and suspended by the left main bronchus to a force-displacement transducer placed in a humidified chamber to allow monitoring of weight changes. An MMS 107 respirator (S.N.E.H., Gonesse, France) set at 20 breaths/min with a tidal volume of 200 mL and a positive end-expiratory pressure of 2 cm H2O was used to ventilate the left lung with a humidified warm gas mixture (20% oxygen, 75% nitrogen, and 5% carbon dioxide). The lung was perfused with 300 mL of heparinized autologous blood through a cannula placed in the left pulmonary artery. A constant flow of 0.03 mL/g body weight was maintained with a peristaltic pump (Ismatec; Bioblock, Strasbourg, France) placed in series with the arterial line. Venous blood was collected by gravity into a reservoir through a cannula in the left atrium and was recirculated for 60 minutes. To prevent loss of reservoir volume through retrograde perfusion of the bronchial circulation, the bronchial arteries were ligated. PAP and pulmonary venous pressure (PVP) were continuously monitored with pressure transducers (model P23 ID) placed proximal to the lung, on the arterial line and on the venous line, respectively. Pressure signals were amplified (model M52; Telco) and recorded on a polygraph recorder (Solar 8000, Marquette, Milwaukee, Wis). Zone 3 conditions (arterial > venous > alveolar pressures) were maintained throughout all experiments.
Measurements of pulmonary hemodynamics and microvascular lung permeability
Pulmonary capillary pressure (Pc') was estimated with the double-occlusion method.
20 With this method, after simultaneous occlusion of the arterial and venous line, PAP and PVP equilibrate to the same pressure, which is well correlated with Pc'. Pulmonary arterial resistance (Ra) and venous resistance (Rv) were calculated as follows:
Ra = (PAP - Pc')/Q
Rv = (Pc' - PVP)/Q
where Q is the flow.
The filtration coefficient (Kfc) was used as an index of endothelial permeability to fluid and was measured by the isogravimetric method described by Hakim and Kelly.
21 Briefly, after an isogravimetric period of 30 minutes, PVP was rapidly increased by 20 cm H2O for 20 minutes by raising the outflow end of the venous reservoir connected to the left atrial cannula. The resultant increase in lung weight was recorded. The characteristic rapid weight gain from vascular bed filling was followed by a phase of slower weight gain reflecting filtration of fluid into the pulmonary interstitium. The rate of slow weight change (
W/
t) was analyzed with linear regression of the log10-transformed weight changes per minute. The initial rate of weight gain was calculated by extrapolating
W/
t to time 0. Kfc was obtained by dividing
W/
t at time 0 by the change in Pc' that occurred after the venous outflow pressure increase, normalizing the result for the baseline wet lung weight, and expressing it in milliliters per minute per centimeter of water per 100 g lung tissue. Baseline wet lung weight was estimated by measuring the weight of the left lung at the beginning of the experiment and subtracting the weight of the extrapulmonary tissue measured after reperfusion.
Statistical analysis
Results are expressed as mean ± SD. Comparison were performed with paired and unpaired 2-way analysis of variance. The Spearman rank correlation test was performed to assess any correlation between lung VEGF values and Kfc.
| Results |
|---|
|
|
|---|
|
|
Maximal relaxation response to acetylcholine was reduced after bypass to 30% of control values (P < .0001; Figure 1). EC50 for acetylcholine was nearly unchanged before and after CPB, ranging from 8.5 10-8 to 1.8 10-7 mol/L. These results indicate that endothelium-dependent relaxation of pulmonary artery was impaired after CPB. Addition of L-NAME significantly reduced the relaxation in control vascular rings, but to a less extent that in post-CPB pulmonary vessels (from 55.5% ± 5.96% to 18.5% ± 4.1% of relaxation in control pulmonary arterial rings vs when L-NAME was added and from 15.44% ± 4.8% to 6.26% ± 3.7% in post-CPB rings, P = .04)
|
|
|
| Discussion |
|---|
|
|
|---|
In vitro experiments on arterial rings showed that endothelium-dependent vasodilatation to acetylcholine was blunted after CPB. Acetylcholine, through membrane muscarinic receptors, activates G protein, which subdivides in
and ß subunits. This in turns activates the phospholipase C and inositol pathway, which eventually mobilizes calcium from intracellular stores. Increases in intracellular calcium then activate NOS, leading to nitric oxide production. On the other side, calcium ionophore is not a receptor-dependent agonist and itself leads to an increase in intracellular calcium. Therefore in pulmonary arterial rings after total CPB it appears that the signal transduction from membrane receptors to increased intracellular calcium is impaired. This approach was previously used by Evora and associates
22 in coronary arteries rings to demonstrate G protein dysfunction after myocardial ischemia and reperfusion in the dog. In addition, Chang and colleagues
23 showed that G protein dysfunction could be attenuated by continuous warm blood cardioplegia. This finding has, however, to the best of our knowledge not been demonstrated in the pulmonary vascular bed after CPB. As a preliminary report, one may conclude that CPB through lung ischemia-reperfusion injury is responsible for endothelial G protein dysfunction, leading to an impairment of signal transduction from the membrane receptor to the intracellular calcium mobilization.
On the other side, VEGF through its membrane tyrosine kinase receptors activates the phospholipase C and inositol pathway that mobilizes calcium from intracellular stores without any activation of G protein.
24 Therefore the finding that after CPB there is a pulmonary accumulation of VEGF that does not in turn promote endothelial nitric oxide secretion means that post-CPB pulmonary artery endothelial dysfunction is due to endothelial membrane lesion. In vitro dissection of these processes to point out the impaired sequence of signal transduction is still under evaluation. Indeed, cellular membrane lesions have been documented after ischemia-reperfusion.
25 The following sequence of events can be therefore proposed. During CPB, the lungs are subjected to an ischemic process because there is no more antegrade flow through the main pulmonary artery, mimicked in our model by crossclamping of the pulmonary artery, and bronchial collaterals do not have enough flow to provide adequate lung perfusion. This phenomenon triggers the production of hypoxia-inducible factor 1,
13,26 which in turns activates production of VEGF and expression of VEGF receptors within the ischemic territory.
27 Endothelial cell ischemia-reperfusion leads to membrane lesions and induces a dysfunction in signal transduction leading to nitric oxide production. Attempts at producing pulmonary arterial ring vasodilatation with increasing doses of VEGF were unsuccessful in this model either before or after CPB. Therefore no pharmacologic in vitro data were available to demonstrate the interaction between VEGF and nitric oxide. Tofukuji and colleagues
28 showed that during myocardial ischemia VEGF messenger RNA is upwardly regulated, as is flk-1 messenger RNA. They also demonstrated that, despite ischemia and reperfusion, relaxation of preconstricted coronary arterioles to VEGF was statistically significantly augmented and remained unchanged after use of receptor-mediated endothelium-dependent vasodilator adenosine diphosphate, which contrasts with the results of Chang and associates.
23 The difference in results may be multifactorial. First, microvessels contain less smooth muscle and might be more sensitive to vasodilator agonists than 2-mm diameter pulmonary arterial rings. Second, in their model Tofukuji and colleagues
28 showed this particular type of vascular reactivity after use of cardioplegia, whereas in this study lungs were not subjected to any type of pharmacologic protection. Finally, coronary and pulmonary circulations may display different responses to vasodilators after ischemia and reperfusion.
Other possible explanations for the lack of nitric oxide production related to VEGF accumulation might be an endothelial NOS dysfunction, which was ruled out by the calcium ionophore data; a downward regulation of VEGF receptors, but none of our data can confirm or disconfirm this hypothesis; or a questionable relationship between VEGF and nitric oxide in the pulmonary vasculature, which might be answered by use of a VEGF blocker; however, this type of molecule is under experimentation in other medical fields and was not available for our work. Finally, the fact that acetylcholine is unable to relax pulmonary arterial rings after CPB may simply be due to a downward regulation of muscarinic receptors.
An additional probable effect of lung VEGF accumulation was an increase in Kfc. Indeed, VEGF was previously known to be the vascular permeability factor, a protein that promotes extravasation of proteins from tumor-associated blood vessels. This observation is consistent with the finding of increased lung water content after CPB and explains some postoperative ventilatory problems. A statistically significant correlation between these findings was found. VEGF has already been investigated as a potential source of edema formation in the heart
28 and brain
29 after the ischemia-reperfusion phenomenon. This correlation was even more relevant when muscular VEGF was shown not to be statistically significantly increased after bypass. This suggests that because skeletal muscles are not subjected to ischemia during CPB, only ischemic territories express VEGF accumulation, either through production or through higher receptor expression or affinity. A recent work by Abrahamov and coworkers
30 showed an independent correlation between plasma VEGF and capillary leak syndrome in neonates after CPB. This finding is not in contrast with those of our work, because some soluble VEGF can be found in the systemic circulation as a result of the excess in the vicinity of the stressed territories.
In conclusion, this study demonstrates that total CPB induces pulmonary hypertension with a pulmonary vascular endothelial dysfunction through a multifactorial mechanism that mainly includes ischemia-reperfusion phenomenon and cytokine production. In addition to vasoconstrictors cytokines endothelin 1 and thromboxane previously demonstrated to intervene in this reaction,
31 this work shows that it is also probably related to membrane alterations or G protein dysfunction, which in turns impairs signal transduction, leading to nitric oxide production with an accumulation of upstream products. One of these products is VEGF, which also increases vascular permeability and is probably (in addition to other factors) responsible for post-CPB pulmonary edema, a finding that is less pronounced in the systemic nonischemic territories.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
M. Godzich, M. Hodnett, J. A. Frank, G. Su, M. Pespeni, A. Angel, M. B. Howard, M. A. Matthay, and J. F. Pittet Activation of the stress protein response prevents the development of pulmonary edema by inhibiting VEGF cell signaling in a model of lung ischemia-reperfusion injury in rats FASEB J, July 1, 2006; 20(9): 1519 - 1521. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |